Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 9 of about 9   

Articles published

DVAX 15.12 +0.78 (5.44%)
price chart
Dynavax (DVAX): Hepatitis B Vaccine Drug Application Accepted For Review In ...
(By Balaseshan) Dynavax Technologies Corp. (NASDAQ:DVAX) said the European Medicines Agency has accepted the filing of marketing authorization application for hepatitis B vaccine drug, HEPLISAV.
Related articles »  
7 Small Cap Stocks Holding Low Debt Ratios And Positive Analyst Ratings
The Long Term Debt/Equity Ratio is a variation of the traditional debt-to-equity ratio; this value computes the proportion of a company's long-term debt compared to its available capital. By using this ratio, investors can identify the amount of ...
Related articles »  
People Moves: September 2012
Dynavax announced the appointment of Christine Larson to the position of vice president and chief financial officer, a newly created position.
Hepatitis C Drug Companies and All-Oral Treatment: A $20 Billion Market
My main reason for thinking a sustainable stock rebound is possible was because it's a top-ten holding of value-investing legend Seth Klarman, who owns a 9.2% stake in the company (10 million shares) at an average purchase price of $8 per share (30% ...
Related articles »  
5 Pharmaceutical Companies With PDUFA Dates In Q1/2013
In addition to NP101, NuPathe has two proprietary product candidates based on its LAD, or Long-Acting Delivery, biodegradable implant technology that allows delivery of therapeutic levels of medication over a period of months with a single dose. NP201 ...
Related articles »  
Glaxo to Sell Classic Brands to Aspen - Analyst Blog
recently announced that it has entered into an agreement with Aspen Global Incorporated, a subsidiary of Aspen Pharmacare Holdings Limited to divest the majority of its Classic Brands in Australia.
Related articles »  
Interest Rates Going Nowhere, Home Depot CFO Says
Home Depot could issue another $2 billion in debt and still remain below its maximum desired leverage ratio, but Chief Financial Officer Carol Tome said interest rates won't be moving up from their near-historic lows anytime soon, so the company doesn ...
Generic Xopenex Launch by Watson - Analyst Blog
recently announced the launch of an authorized generic version of Sunovion Pharmaceuticals Inc.'s Xopenex (levalbuterol HCl) inhalation solution.
Related articles »  
Macaulay in the spotlight � Culkin is not in as much trouble as he seems
Top News: Intellicheck Mobilisa (NYSEMKT:IDN), j2 Global (NASDAQ:JCOM), Dynavax Technologies Corpora... Investors Watch ... Momentum Stocks : Microchip Technology (NASDAQ:MCHP), Unisys Corporation (NYSE:UIS), Collectors Univ... Traders Are ...
Related articles »